Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

0.9390 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,934
Open 0.9390
Bid (Size) 0.9400 (5,500)
Ask (Size) 0.9456 (100)
Prev. Close 0.9390
Today's Range 0.9390 - 0.9390
52wk Range 0.7560 - 8.969
Shares Outstanding 3,541,262
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ensysce Biosciences Expands Global Opioid Patent Portfolio
Via ACCESS Newswire
News headline image
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
Via ACCESS Newswire

Performance

YTD
-0.1%
-0.1%
1 Month
-20.4%
-20.4%
3 Month
-59.5%
-59.5%
6 Month
-57.3%
-57.3%
1 Year
-88.3%
-88.3%

More News

Read More
News headline image
Ensysce Biosciences Issues Annual Shareholder Letter
Via ACCESS Newswire
News headline image
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Via ACCESS Newswire
News headline image
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
Via ACCESS Newswire
News headline image
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
Via ACCESS Newswire
News headline image
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
Via ACCESS Newswire
News headline image
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
Via ACCESS Newswire
News headline image
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Narrows Loss in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
Via ACCESS Newswire
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
Via ACCESS Newswire
News headline image
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Ensysce Biosciences Reports First Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
Via ACCESS Newswire

Frequently Asked Questions

Is Ensysce Biosciences, Inc. - Common Stock publicly traded?
Yes, Ensysce Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Ensysce Biosciences, Inc. - Common Stock trade on?
Ensysce Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ensysce Biosciences, Inc. - Common Stock?
The ticker symbol for Ensysce Biosciences, Inc. - Common Stock is ENSC on the Nasdaq Stock Market
What is the current price of Ensysce Biosciences, Inc. - Common Stock?
The current price of Ensysce Biosciences, Inc. - Common Stock is 0.9390
When was Ensysce Biosciences, Inc. - Common Stock last traded?
The last trade of Ensysce Biosciences, Inc. - Common Stock was at 01/20/26 04:00 PM ET
What is the market capitalization of Ensysce Biosciences, Inc. - Common Stock?
The market capitalization of Ensysce Biosciences, Inc. - Common Stock is 3.33M
How many shares of Ensysce Biosciences, Inc. - Common Stock are outstanding?
Ensysce Biosciences, Inc. - Common Stock has 3M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.